C. Boyd Clarke
Chairman at FluGen, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul V. Radspinner | M | - |
FluGen, Inc.
 FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | 17 years |
| Richard Douglas | M | 71 | 8 years | |
| Martin Joyce | M | 70 | 11 years | |
| Patricia Russo | F | 71 | 29 years | |
| Eric Patzer | M | 75 |
MedImmune Vaccines, Inc.
 MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA
FluGen, Inc.
FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | 7 years |
| Caroline Litchfield | F | 55 | 34 years | |
| Paul Weiss | M | 66 |
FluGen, Inc.
FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | - |
| David G. Walsh | M | - |
FluGen, Inc.
FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | - |
| Pamuk Bilsel | M | - |
FluGen, Inc.
FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | - |
| Erik Iverson | M | 56 |
FluGen, Inc.
FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | - |
| David A. Newberg | M | - |
FluGen, Inc.
FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | - |
| Renee Herber | F | - |
FluGen, Inc.
FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | 9 years |
| Robert Belshe | M | - |
FluGen, Inc.
FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert P. Luciano | M | - | 23 years | |
| Kenneth Frazier | M | 69 | 30 years | |
| Richard Kogan | M | 81 | 21 years | |
| P. Vagelos | M | 94 | 19 years | |
| J. Read | M | 73 |
MedImmune Vaccines, Inc.
MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA | - |
| Raymond Gilmartin | M | 82 | 2 years | |
| Philip S. Schein | M | 84 |
U.S. Bioscience, Inc.
 U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA. | 11 years |
| Stephen Tulipano | M | 65 | 4 years | |
| Jeffrey Meckler | M | 57 |
QLT, Inc.
 QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 4 years |
| Jason Aryeh | M | 55 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| John Kozarich | M | 74 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| Fred M. Haney | M | - |
NovaDigm Therapeutics, Inc.
 NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 5 years |
| Paul Hastings | M | 64 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 4 years |
| David Gionco | M | 63 | 3 years | |
| Stephen Sabba | M | 64 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| Ian John Massey | M | 73 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 6 years |
| Richard Markham | M | 73 | 20 years | |
| Marino Carol | F | - | 8 years | |
| Bruce Carter | M | 80 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 6 years |
| Geoffrey F. Cox | M | 80 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| Charlene Andors Friedman | F | 66 |
MedImmune Vaccines, Inc.
MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA | 2 years |
| Kathryn Falberg | F | 63 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 3 years |
| David Climie | M | - |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| Donald S. Brooks | M | 88 | - | |
| Joseph Romanelli | M | 50 | 19 years | |
| Martha Manning | F | 69 |
U.S. Bioscience, Inc.
U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA. | 6 years |
| John Thomas | M | 70 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| Paul Neff | M | 72 |
Neose Technologies, Inc.
 Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 9 years |
| Dori Christine Assaly | F | - |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| John J Horan | M | - | 6 years | |
| Robert I. Kriebel | M | 81 |
U.S. Bioscience, Inc.
U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA.
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 12 years |
| Caroline Dorsa | F | 64 | 22 years | |
| Richard Henriques | M | 68 | 27 years | |
| Kenneth Bartizal | M | 72 | 20 years | |
| Sukhi Jagpal | M | 50 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 12 years |
| Oscar Ferenczi | M | 60 | - | |
| Berta Strulovici | M | - | - | |
| Egil Bodd | M | 69 | 11 years | |
| Thomas Moriarty | M | 60 | - | |
| Ray Hill | M | 79 | 18 years | |
| Tom Caskey | M | - | 6 years | |
| Christine Cioffe | F | - | 20 years | |
| George McAllister | M | - | 17 years | |
| Sandy Tremps | F | - | 33 years | |
| Carole A. Sable | M | 62 | 12 years | |
| Ron Newbold | M | - | 13 years | |
| Lee Ausburn | F | - | 26 years | |
| Kyu-Sung Lee | M | 64 | 10 years | |
| David A. Esposito | M | 55 | 13 years | |
| Karen Quintos | F | 60 | 4 years | |
| Daniel R. Martin | M | - | 8 years | |
| Valerie Sharice Grant | F | - | 2 years | |
| Gregory L. Tewalt | M | - | 18 years | |
| Wei Tang | M | - | 15 years | |
| Lisa Escudero | F | 62 | 18 years | |
| James F. Fuqua | M | - | 31 years | |
| Barry Gertz | M | 72 | 28 years | |
| Clark Golestani | M | 57 | 24 years | |
| Zofia E. Dziewanowska | M | 82 | - | |
| Wendy Perrow | F | 66 | 14 years | |
| Samuel O. Thier | M | 86 | 16 years | |
| Michael Atieh | M | 70 | 19 years | |
| Robert Segal | M | 66 | - | |
| Celia A. Colbert | F | 67 | - | |
| Bradley Sheares | M | 67 | 19 years | |
| Stefan Oschmann | M | 66 | 20 years | |
| Adam Schechter | M | 59 | 30 years | |
| William G. Bowen | M | 90 | 21 years | |
| Larry Bossidy | M | 89 | 14 years | |
| Judy Lewent | F | 75 | 27 years | |
| John L. Zabriskie | M | 85 | 6 years | |
| Johnnetta Betsch Cole | M | 87 | 15 years | |
| David S. Doll | M | - | 8 years | |
| Luc Grégoire | M | 64 | - | |
| Michael Rosenblatt | M | 76 | 32 years | |
| Douglas J. MacMaster | M | 93 | 31 years | |
| Michael R. Goldberg | M | - | 17 years | |
| Ian M. Miller | M | - | 11 years | |
| Ed M. Scolnick | M | 83 | 20 years | |
| Paul Ronald Bell | M | 76 | 14 years | |
| Horace D. Nalle | M | - | - | |
| Bernard J. Kelley | M | 82 | 10 years | |
| Lars Kåre Viksmoen | M | 75 | 14 years | |
| Franz Hefti | M | 76 | 7 years | |
| Gerald L. Wisler | M | 67 | 20 years | |
| Kamil Ali-Jackson | F | 65 | 8 years | |
| John Kapp | M | - | 13 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 87 | 87.00% |
| Canada | 13 | 13.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- C. Boyd Clarke
- Personal Network
